GenVec Inc (GNVC.OQ) Company Profile | Reuters.com
Edition:
United States

Profile: GenVec Inc (GNVC.OQ)

GNVC.OQ on NASDAQ Stock Exchange Capital Market

0.58USD
27 Jun 2016
Change (% chg)

-- (--)
Prev Close
$0.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,338
52-wk High
$3.69
52-wk Low
$0.36

GenVec, Inc. (GenVec), incorporated on December 7, 1992, is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations.

Hearing and Balance Program

In collaboration with Novartis Institutes for BioMedical Research, Inc. (Novartis), the Company's hearing and balance disorders program is involved in the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. In multiple animal models, the Company has demonstrated formation of new inner ear sensory hair cells and the restoration of hearing and balance function using its technology to deliver the Atoh1 gene to the inner ear. The Company's lead product candidate in this category is CGF166.

Vaccine Programs

The Company develops vaccines using its AdenoVerse technology. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing a vaccine against Enterovirus D68 (EV-D68). EV-D68 is a virus that can cause respiratory illness in children. The Company is engaged in the development of GV2311, a vaccine against RSV, and GV2207 vaccines for the treatment of HSV, which include HSV Type 2 (HSV-2).

Animal Health Product Development Program

The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. The FMD vaccine approach utilizes the Company's Adenovector technology. The FMD vaccines are manufactured on a GenVec cell line that is capable of producing antigens without the use of FMD virus.

The Company competes with Sanofi S.A., Novartis, GlaxoSmithKline plc, AstraZeneca Biopharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bavarian Nordic A/S, Intercell A.G., Genocea BioSciences Inc., Vical Incorporated, Emergent Biosolutions Inc., Sentient Pharmaceuticals, Inc., AlphaVax Inc., NanoBio Corporation, Coridon Pty Ltd., Merial Limited, Bayer AG, Indian Immunological Ltd., Sanaria and Novavax Inc.

Company Address

GenVec Inc

910 Clopper Rd Ste 220n
GAITHERSBURG   MD   20878-1353
P: +1240.6320740
F: +1240.6320735

Company Web Links